Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

CML, BCR/ABR Studies and Myeloproliferative Disorders

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders

Leukemia volume 20, pages 471–476 (2006)Cite this article

Abstract

A mutation in the JH2 pseudokinase domain of the Janus kinase 2 gene (JAK2 V617F) has been described in chronic myeloproliferative disorders (MPD). We screened 79 acute myeloid leukemia (AML) cell lines and found five positive for JAK2 V617F (HEL, MB-02, MUTZ-8, SET-2, UKE-1), 4/5 with histories of MPD/MDS. While SET-2 expressed both mutant (mu) and wild-type (wt) JAK2, remaining positives carried homo-/hemizygous JAK2 mutations. Microsatellite analysis confirmed losses of heterozygosity (LOH) affecting the JAK2 region on chromosome 9p in MB-02, MUTZ-8 and UKE-1, but also in HEL, the only JAK2mu cell line lacking any reported MPD/MDS history. All five JAK2mu cell lines displayed cytogenetic hallmarks of MDS, namely losses of 5q or 7q, remarkably in 4/5 cases affecting both chromosomes. Our combined FISH and microsatellite analysis uncovered a novel mechanism to supplement mitotic recombination previously proposed to explain JAK2 LOH, namely chromosome deletion with/without selective JAK2mu amplification. Confirming the importance of the mutated JAK2 protein for growth and prevention of apoptosis, JAK2mu cell lines displayed higher sensitivities to JAK2 inhibition than JAK2wt cell lines. In summary, JAK2 V617F cell lines, derived from patients with history of MPD/MDS, represent novel research tools for elucidating the pathobiology of this JAK2 mutation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Baxter EJ, Scott LM, Campbell PJ . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.

    Article  CAS  PubMed  Google Scholar 

  2. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thromobocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.

    Article  CAS  PubMed  Google Scholar 

  3. James C, Ugo V, LeCouedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.

    Article  CAS  PubMed  Google Scholar 

  4. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.

    Article  CAS  PubMed  Google Scholar 

  5. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162–2168.

    Article  CAS  PubMed  Google Scholar 

  6. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia. Blood 2005; 106: 3370–3373.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both ‘atypical’ myeloproliferative disorders and the myelodysplastic syndrome. Blood 2005; 106: 1207–1209.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Levine RL, Loriaux M, Huntly BJP, Loh ML, Beran M, Stoffregen E et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377–3379.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93: 385–395.

    Article  CAS  PubMed  Google Scholar 

  10. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997; 90: 2535–2540.

    CAS  PubMed  Google Scholar 

  11. Nunez CA, Zipf TF, Roberts WM, Medeiros LJ, Hayes K, Bueso-Ramos CE . Molecular monitoring of cerebrospinal fluid can predict clinical relapse in acute lymphoblastic leukemia with eosinophilia. Arch Pathol Lab Med 2003; 127: 601–605.

    PubMed  Google Scholar 

  12. Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005; 65: 2662–2667.

    Article  CAS  PubMed  Google Scholar 

  13. Drexler HG, Dirks W, MacLeod RAF, Quentmeier H, Steube KG, Uphoff CC . DSMZ Catalogue of Human and Animal Cell Lines, 8th edn. DSMZ: Braunschweig, Germany, 2001.

    Google Scholar 

  14. Drexler HG . The Leukemia-Lymphoma Cell Line Factsbook. Academic Press: San Diego, CA, 2000.

    Google Scholar 

  15. MacLeod RAF, Drexler HG . Cytogenetic analysis of cell lines. Methods Mol Biol 2005; 290: 51–70.

    CAS  PubMed  Google Scholar 

  16. Quentmeier H, Martelli MP, Dirks WG, Bolli N, Liso A, MacLeod RAF et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 2005; 19: 1760–1767.

    Article  CAS  PubMed  Google Scholar 

  17. Quentmeier H, Zaborski M, Drexler HG . Effects of thrombopoietin, interleukin-3 and the kinase inhibitor K-252a on growth and polyploidization of the megakaryocytic cell line M-07e. Leukemia 1998; 12: 1603–1611.

    Article  CAS  PubMed  Google Scholar 

  18. Hu ZB, MacLeod RAF, Meyer C, Quentmeier H, Drexler HG . New acute myeloid leukemia-derived cell line: MUTZ-8 with 5q−. Leukemia 2002; 16: 1556–1561.

    Article  CAS  PubMed  Google Scholar 

  19. Uozumi K, Otsuka M, Ohno N, Moriyama T, Suzuki S, Shimotakahara S et al. Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles. Leukemia 2000; 14: 142–152.

    Article  CAS  PubMed  Google Scholar 

  20. Fiedler W, Henke RP, Ergün S, Schumacher U, Gehling UM, Vohwinkel G et al. Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome. Cancer 2000; 88: 344–351.

    Article  CAS  PubMed  Google Scholar 

  21. Charrin C . del(5q) in myeloid malignancies. Atlas Genet Cytogenet Oncol Haematol 1998, URL: http://www.infobiogen.fr/services/chromcancer/Anomalies/del5qID1092.html.

  22. MacLeod RAF, Dirks WG, Reid YA, Hay RJ, Drexler HG . Identity of original and late passage Dami megakaryocytes with HEL erythroleukemia cells shown by combined cytogenetics and DNA fingerprinting. Leukemia 1997; 11: 2032–2038.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. DSMZ-German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany

    H Quentmeier, R A F MacLeod, M Zaborski & H G Drexler

Authors
  1. H Quentmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R A F MacLeod
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Zaborski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H G Drexler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Quentmeier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Quentmeier, H., MacLeod, R., Zaborski, M. et al. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 20, 471–476 (2006). https://doi.org/10.1038/sj.leu.2404081

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404081

Keywords

This article is cited by

Search

Advanced search

Quick links